Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate

E-ISSN： 1346-8138|42|3|338-339

ISSN： 0385-2407

Source： THE JOURNAL OF DERMATOLOGY, Vol.42, Iss.3, 2015-03, pp. : 338-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

miRNA Expression Correlated with Morphological Findings in Chronic Myeloid Leukemia Treated with Imatinib Mesylate

Acta Haematologica, Vol. 131, Iss. 1, 2013-09 ,pp. : 11-15

Karger

Access to resources Recommend Favorite

Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment

Acta Haematologica, Vol. 117, Iss. 4, 2006-12 ,pp. : 191-196

Karger

Access to resources Recommend Favorite

Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia

Acta Haematologica, Vol. 118, Iss. 4, 2007-11 ,pp. : 205-208

Karger

Access to resources Recommend Favorite

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

By Goldberg Stuart L. Chen Lei Guerin Annie Macalalad Alexander R. Liu Nathan Kaminsky Michael Ericson Solveig G. Wu Eric Q.

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1075-1082

Informa Healthcare

Access to resources Recommend Favorite

Imatinib Mesylate Resistance in a Chronic Myeloid Leukemia Patient with a Novel e8a2 BCR-ABL Transcript Variant

Acta Haematologica, Vol. 120, Iss. 3, 2008-11 ,pp. : 146-149

Karger

Access to resources Recommend Favorite